Jazz Pharmaceuticals CEO Bruce Cozadd's 2021 pay jumps 25% to $16M
Jazz Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: June 10, 2022
Jazz Pharmaceuticals reported fiscal year 2021 executive compensation information on June 10, 2022.
In 2021, five executives at Jazz Pharmaceuticals received on average a compensation package of $6.8M, a 27% increase compared to previous year.
Average pay of disclosed executives at Jazz Pharmaceuticals
Bruce C. Cozadd, Chief Executive Officer, received $16M in total, which increased by 25% compared to 2020. 86% of Cozadd's compensation, or $13M, was in stock awards. Cozadd also received $1.2M in non-equity incentive plan, $1.1M in salary, as well as $25K in other compensation.
For fiscal year 2021, the median employee pay was $212,134 at Jazz Pharmaceuticals. Therefore, the ratio of Bruce C. Cozadd's pay to the median employee pay was 74 to one.
Daniel N. Swisher, Jr, President, received a compensation package of $5.4M, which increased by 21% compared to previous year. 77% of the compensation package, or $4.1M, was in stock awards.
Renée Gal, Chief Financial Officer, earned $4.6M in 2021, a 12% increase compared to previous year.
Chris Tovey, Chief Operating Officer, received $4.2M in 2021.
Robert Iannone, M.D., M.S.C.E, Executive Vice President, Global Head of Research and Development, earned $4M in 2021, a 27% increase compared to previous year.
Related executives
Bruce Cozadd
Jazz Pharmaceuticals
Chief Executive Officer
Daniel Swisher
Jazz Pharmaceuticals
President
Renée Gal
Jazz Pharmaceuticals
Chief Financial Officer
Robert MSCE
Jazz Pharmaceuticals
Executive Vice President, Global Head of Research and Development
Chris Tovey
Jazz Pharmaceuticals
Chief Operating Officer
You may also like
Source: SEC filing on June 10, 2022.